InMode Ltd vs Vaxcyte Inc. Common Stock — how do they compare? InMode Ltd trades at $14.29 (market cap $823.46M), while Vaxcyte Inc. Common Stock trades at $67.37 (market cap $10.51B). The key difference: Vaxcyte Inc. Common Stock is far larger — about 12.8× InMode Ltd's market cap, and Vaxcyte Inc. Common Stock is trading nearer its 52-week high, InMode Ltd nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold InMode Ltd for 28 Days and Vaxcyte Inc. Common Stock for 0 Days on average.
| INMD | PCVX | |
|---|---|---|
Market Cap | $823.46M | $10.51B |
Volume | 427,627 | 2,644,694 |
Sector | Health | Health |
52-Week High | $16.62 | $73.82 |
52-Week Low | $12.76 | $40.32 |
Typical Hold Time | 28 Days | 0 Days |
Enterprise Value | $326.79M | $9.14B |
Signals from Pluang's Aura AI — not financial advice
InMode (INMD) trades at $14.305, showing minimal daily movement with a 0.03% gain. The stock maintains a bullish technical signal despite mixed indicators, with RSI suggesting mild overbought conditions. Fundamentally, the company demonstrates strong profitability with 76.52% gross margins and 20.69% net income margins, though 2026 guidance shows potential margin compression. Recent developments include the launch of Morpheus8 Cool technology and an unsolicited acquisition offer from Steel Partners at $16.75 per share in July 2026.
The investment outlook balances attractive valuation metrics (P/E of 11.83, EV/EBITDA of 4.68) against cyclical industry headwinds and management capital allocation concerns. Analyst sentiment is divided with 45% buy ratings, while technicals suggest near-term consolidation around current levels. Key risks include US platform sales decline and execution on international growth strategy.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
InMode provides innovative medical technologies for minimally invasive surgical procedures. Its platforms use radiofrequency (RF) energy for aesthetic treatments like body contouring and skin tightening.
Read more on INMD →Vaxcyte, Inc. is a clinical-stage vaccine company that engineers protein-based vaccines to prevent bacterial diseases such as invasive pneumococcal disease, using its proprietary cell-free protein synthesis platform to develop candidates including the pneumococcal conjugate vaccines VAX-31 and VAX-24.
Read more on PCVX →